Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00259-010-1631-xPMID 21052661
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 90Y-edotreotide for metastatic carcinoid refractory to octreotide.

  2010cited by this paper
• Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

  2010cited by this paper
• Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention

  2010cited by this paper
• Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate

  2010cited by this paper
• Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience.

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience

  2009cited by this paper
• Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

  2009influential reference
• Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target Tissues

  2009cited by this paper
• Lutetium-177 octreotate radiopeptide therapy of endocrine cancer: Tumor and critical organ dosimetry

  2009cited by this paper
• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

  2009cited by this paper
• Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience.

  2009cited by this paper
• First-line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide

  2008cited by this paper
• Neuroendocrine tumors of the diffuse neuroendocrine system

  2008cited by this paper
• Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

  2008cited by this paper
• Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

  2008cited by this paper
• Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

  2008cited by this paper
• Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

  2008influential reference
• et al Treatment with the radiolabeled somatostatinanalog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival Journal of Clinical Oncology :

  2008cited by this paper
• Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma.

  2007cited by this paper
• Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code

  2006cited by this paper
• The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?

  2006cited by this paper
• Therapeutic options for gastrointestinal carcinoids.

  2006cited by this paper
• Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study.

  2006cited by this paper
• Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets.

  2005cited by this paper
• Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

  2005cited by this paper
• OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

  2005cited by this paper
• A Software Tool for Specifying Voxel Models for Dosimetry Estimation

  2003cited by this paper
• A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.

  2003cited by this paper
• Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities

  2003cited by this paper
• Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

  2002cited by this paper
• Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

  2000cited by this paper
• Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes.

  2000cited by this paper
• MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee.

  1999cited by this paper
• Two-sided confidence intervals for the single proportion: comparison of seven methods.

  1998cited by this paper
• Carcinoid metastases to the liver: role of triple-phase helical CT.

  1998cited by this paper
• MIRDOSE: personal computer software for internal dose assessment in nuclear medicine.

  1996cited by this paper
• Tolerance of normal tissue to therapeutic irradiation.

  1991cited by this paper
• Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.

  1979cited by this paper
• Probable Inference, the Law of Succession, and Statistical Inference

  1927cited by this paper

• Expanding horizons in theragnostics: from oncology to multidisciplinary applications

  2025cites this paper
• Response Evaluation Criteria in Grade 1/2 Neuroendocrine Tumors (RECIN).

  2025cites this paper
• Pharmacological Enhancement of Radionuclide Therapy Using Radiopharmaceutical-Drug Combinations in Oncology.

  2025cites this paper
• Superior Response of CAP-PRRT of G3 NET When Switching to the Somatostatin Receptor Antagonist LM3: Intraindividual Proof-of-concept.

  2025cites this paper
• 177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial

  2025cites this paper
• Neuroendocrine Tumors: Beta Labeled Radiopeptides.

  2025cites this paper
• Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors

  2025cites this paper
• Frontiers in radiopharmaceuticals for neuroendocrine tumors

  2025cites this paper
• Nuklearmedizinische Therapien bei neuroendokrinen Tumoren

  2025cites this paper
• 177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial

  2025cites this paper
• The Randomized, Phase 2 Trial LuCAP Study

  2025cites this paper
• Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies.

  2024cites this paper
• Structure and Function of Somatostatin and its Receptors in Endocrinology.

  2024cites this paper
• Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience

  2024cites this paper
• Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update

  2024cites this paper
• Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis

  2024cites this paper
• Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives.

  2024cites this paper
• Theranostic Innovation by Humane N-of-One Cancer Care in Real-World Patients

  2024cites this paper
• Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide

  2024cites this paper
• Combination Strategies and Targeted Radionuclide Therapies.

  2024cites this paper
• Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023

  2024cites this paper
• A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177Lutetium-DOTA-octreotate radionuclide therapy

  2023cites this paper
• Cancer Care by Committee to be Superseded by Personal Physician–Patient Partnership Informed by Artificial Intelligence

  2023cites this paper
• Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approaches

  2023cites this paper
• Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review

  2023cites this paper
• Molecular imaging Theranostics of Neuroendocrine Tumors.

  2023cites this paper
• Next Generation Radiotheranostics Promoting Precision Medicine.

  2023cites this paper
• Theranostics in Neurooncology: Heading Toward New Horizons

  2023cites this paper
• Heterogeneity of absorbed dose distribution in kidney tissues and dose–response modelling of nephrotoxicity in radiopharmaceutical therapy with beta-particle emitters: A review

  2023cites this paper
• Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: Actinium-225-DOTATATE and Combined Therapies.

  2023cites this paper
• Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies

  2023cites this paper
• Impact of FDG PET/CT Scan in Changing Management of Well-Differentiated Neuroendocrine Tumors With Ki67 Index Less Than or Equal to 5%

  2022cites this paper
• PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable?

  2022cites this paper
• Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise

  2022cites this paper
• Radiotheranostics in oncology: current challenges and emerging opportunities

  2022cites this paper
• Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review

  2022cites this paper
• Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions

  2022cites this paper
• Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence

  2022cites this paper
• Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors

  2022cites this paper
• Somatostatin Receptor Theranostics for Refractory Meningiomas

  2022cites this paper
• Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors

  2022cites this paper
• Long‐term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu‐octreotate peptide radionuclide therapy

  2022cites this paper
• Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective

  2022cites this paper
• Radiopharmaceuticals for Neuroendocrine Tumors.

  2021cites this paper
• Therapiekonzepte bei fernmetastasierten GEP-NEN – medikamentöse und interventionelle Therapie

  2021cites this paper
• Radioreceptor Therapy

  2021cites this paper
• Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale

  2021cites this paper
• Combination Therapies with PRRT

  2021cites this paper
• Chemotherapy in Neuroendocrine Tumors

  2021cites this paper
• Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

  2021cites this paper
• 177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience

  2021cites this paper
• Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.

  2021cites this paper
• Combination radionuclide therapy: A new paradigm.

  2021cites this paper
• The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials

  2021cites this paper
• Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study

  2021cites this paper
• Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications

  2021cites this paper
• EANM position paper on the role of radiobiology in nuclear medicine

  2021cites this paper
• In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

  2021cites this paper
• Neuroendocrine liver metastases: The role of liver transplantation.

  2021cites this paper
• Peptide radio receptor therapy: The huff and puff strategy of neuroendocrine disease management

  2021cites this paper
• Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors

  2021cites this paper
• Peptide Receptor Radionuclide Therapy e Prospects for Personalised Treatment

  2021cites this paper
• [The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)].

  2021cites this paper
• Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment.

  2020cites this paper
• Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors

  2020cites this paper
• Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.

  2020cites this paper
• Combination Strategies to Improve Targeted Radionuclide Therapy

  2020cites this paper
• Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP

  2020cites this paper
• Peptide Receptor Radionuclide Therapy

  2020cites this paper
• Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors

  2020cites this paper
• Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy

  2020cites this paper
• Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy

  2020cites this paper
• Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms

  2020influential citation
• Tailoring Radionuclide Therapy of Neuroendocrine Tumors - Bridging the Gaps

  2020cites this paper
• Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience

  2020cites this paper
• Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward

  2020cites this paper
• Health-related quality of life in neuroendocrine neoplasms: a critical review.

  2020cites this paper
• 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study

  2020cites this paper
• A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report

  2020cites this paper
• Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More

  2019cites this paper
• Patient Eligibility Criteria for PRRT According to the European Neuroendocrine Tumor Society 2017 Guidelines

  2019cites this paper
• Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors

  2019cites this paper
• Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model

  2019cites this paper
• Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors.

  2019cites this paper
• Systemic treatment for lung carcinoids: from bench to bedside

  2019influential citation
• Peptide Receptor Radiotherapy: Current Approaches and Future Directions

  2019cites this paper
• Dual Imaging With 68Ga-DOTATOC and 18F-FDG PET for Planning and Follow-up of PRRT in Combination With Temozolomide Treatment in a Patient With a Metastatic Neuroendocrine Tumor.

  2019cites this paper
• Management of Primary Lymph Nodal Gastrinoma With Liver Metastases Resulting in Zollinger-Ellison Syndrome.

  2019cites this paper
• Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

  2019cites this paper
• Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.

  2019cites this paper
• Local treatment of liver metastases by administration of 177Lu-octreotate via isolated hepatic perfusion - A preclinical simulation of a novel treatment strategy.

  2019cites this paper
• Neoadjuvant chemotherapy for pancreatic neuroendocrine tumors with distant metastases

  2019cites this paper
• Strategies for optimisation of 177Lu-octreotate therapy – exploring local administration and combination therapy regimens

  2019cites this paper
• Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors

  2019cites this paper
• Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours

  2019cites this paper
• Nuclear Medicine Theranostics: Between Atoms and Patients

  2019cites this paper
• Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning

  2018cites this paper
• Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

  2018cites this paper
• Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer

  2018cites this paper
• Recent advances in theranostics and challenges for the future.

  2018cites this paper